Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance.
Data on the subjective responses to neuroleptic treatment and their prognostic implications are reported from a multidimensional double-blind study of the pharmacotherapeutic process in schizophrenia. From these data it seems that the occurrence of a dysphoric response in the course of neuroleptic treatment is associated with a less favorable therapeutic response and long-term prognosis. It is suggested that the dysphoric responders, many of whom belong to the category of nuclear or poor prognosis schizophrenia, may be fundamentally different from the others.
D000328:Adult; D001007:Anxiety / Q000139:chemically induced*; D002746:Chlorpromazine / Q000009:adverse effects* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005260:Female; D006220:Haloperidol / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D012560:Schizophrenia, Catatonic / Q000188:drug therapy; D012562:Schizophrenia, Disorganized / Q000188:drug therapy; D012563:Schizophrenia, Paranoid / Q000188:drug therapy; D012919:Social Behavior / Q000187:drug effects
D006220:Haloperidol; D002746:Chlorpromazine